LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

Search

Prothena Corp PLC

Uždarymo kaina

SektoriusSveikatos priežiūra

5.39 6.52

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

5.01

Max

5.43

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-2.2M

-60M

Pardavimai

705K

2.8M

Pelnas, tenkantis vienai akcijai

-1.12

Pelno marža

-2,128.536

Darbuotojai

163

EBITDA

-682K

-65M

Rekomendacijos

By TipRanks

Rekomendacijos

Pirkti

12 mėnesių prognozė

+380.04% upside

Dividendai

By Dow Jones

Kitas uždarbis

2025-08-07

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-495M

251M

Ankstesnė atidarymo kaina

-1.13

Ankstesnė uždarymo kaina

5.39

Naujienos nuotaikos

By Acuity

50%

50%

167 / 380 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Strong Bearish Evidence

Prothena Corp PLC Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-06-05 20:45; UTC

Uždarbis

Broadcom 2Q Sales Climb on Booming AI Demand

2025-06-05 23:45; UTC

Rinkos pokalbiai

Nikkei May Decline as Caution Over U.S. Economy Continues -- Market Talk

2025-06-05 23:44; UTC

Rinkos pokalbiai

Gold Edges Higher on Weak U.S. Data -- Market Talk

2025-06-05 23:30; UTC

Rinkos pokalbiai

NZME Cost Cuts Can Cushion Effect of Weak Market -- Market Talk

2025-06-05 21:32; UTC

Uždarbis

Broadcom Stock Falls Despite Earnings Beat From AI Chip Maker -- Barrons.com

2025-06-05 20:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2025-06-05 20:45; UTC

Uždarbis

Broadcom Stock Falls Despite Earnings Beat From AI Chip Maker -- Barrons.com

2025-06-05 20:24; UTC

Uždarbis

Broadcom Stock Falls Despite Earnings Beat From AI Chip Maker -- Barrons.com

2025-06-05 20:15; UTC

Uždarbis

Broadcom 2Q Cont Ops EPS $1.03 >AVGO

2025-06-05 20:15; UTC

Uždarbis

Broadcom 2Q Rev $15B >AVGO

2025-06-05 20:15; UTC

Uždarbis

Broadcom 2Q Net $4.97B >AVGO

2025-06-05 20:15; UTC

Uždarbis

Broadcom 2Q Adj EPS $1.58 >AVGO

2025-06-05 20:15; UTC

Uždarbis

Broadcom 2Q EPS $1.03 >AVGO

2025-06-05 20:15; UTC

Uždarbis

Broadcom Sees 3Q Rev $15.8B >AVGO

2025-06-05 20:11; UTC

Įsigijimai, susijungimai, perėmimai

Constellation Energy: Transaction Is Expected to Close in the 4Q >CEG

2025-06-05 20:11; UTC

Įsigijimai, susijungimai, perėmimai

Constellation Energy: Calpine Deal Clears Texas Regulatory Review

2025-06-05 20:11; UTC

Įsigijimai, susijungimai, perėmimai

Constellation Energy: With Approval From PUCT Secured, Transaction Awaits Clearance From NY State Public Service Commission, Federal Energy Regulatory Commission and DOJ >CEG

2025-06-05 19:22; UTC

Rinkos pokalbiai

Oil Futures Resume Upward Moves -- Market Talk

2025-06-05 19:00; UTC

Rinkos pokalbiai

U.S. Natural Gas Settles Lower in Choppy Trade -- Market Talk

2025-06-05 18:32; UTC

Rinkos pokalbiai

Gold Slips After Trump-Xi Call -- Market Talk

2025-06-05 18:26; UTC

Uždarbis

These Stocks Are Moving the Most Today: Broadcom, Tesla, Circle, Brown-Forman, MongoDB, Planet Labs, ChargePoint, Ciena, and More -- Barrons.com

2025-06-05 18:06; UTC

Rinkos pokalbiai

Transpacific Ship Freight Rates Spike on China Tariff Truce -- Market Talk

2025-06-05 16:30; UTC

Įsigijimai, susijungimai, perėmimai

Vallourec Completes The Acquisition Of Thermotite Do Brasil >VK.FR

2025-06-05 16:20; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2025-06-05 16:18; UTC

Rinkos pokalbiai

U.S. Natural Gas Market Shrugs Off Big Storage Build -- Market Talk

2025-06-05 16:15; UTC

Rinkos pokalbiai

Global Commodities Roundup: Market Talk

2025-06-05 16:12; UTC

Rinkos pokalbiai

Global Energy Roundup: Market Talk

2025-06-05 16:12; UTC

Rinkos pokalbiai

Copper Prices Rise on Positive Signals From Trump on China Trade Talks -- Market Talk

2025-06-05 16:03; UTC

Rinkos pokalbiai

U.S. Diesel, Gasoline Futures Pick Back Up -- Market Talk

2025-06-05 15:49; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

Akcijų palyginimas

Kainos pokytis

Prothena Corp PLC Prognozė

Kainos tikslas

By TipRanks

380.04% į viršų

12 mėnesių prognozė

Vidutinis 24.29 USD  380.04%

Aukščiausias 81 USD

Žemiausias 4 USD

Remiantis 9 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Prothena Corp PLC kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

9 ratings

4

Pirkti

4

Laikyti

1

Parduoti

Techninis įvertinimas

By Trading Central

N/A / 7.35Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Strong Bearish Evidence

Vidutinės trukmės periodas

Very Strong Bearish Evidence

Ilgalaikis periodas

Weak Bearish Evidence

Rinkos nuotaikos

By Acuity

167 / 380 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Neutral

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Žemiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Prothena Corp PLC

Prothena Corporation PLC is a late-stage clinical company. The Company is engaged in the protein dysregulation and a pipeline of therapeutics for devastating neurodegenerative and rare peripheral amyloid diseases. It is advancing a pipeline of therapeutic candidates around neurological dysfunction and the biology of misfolded proteins. The Company's clinical pipeline of antibody-based product candidates targets a range of indications, including Birtamimab for the treatment of amyloid light-chain (AL) amyloidosis; prasinezumab for the treatment of Parkinson’s disease and other related synucleinopathies; and PRX004, for the treatment of Transthyretin amyloidosis (ATTR). The Company's pipeline also includes late-preclinical-stage programs targeting proteins implicated in neurological diseases including tau and amyloid beta (Aß) for the treatment of Alzheimer’s disease and other neurodegenerative disorders, and TDP-43 for the treatment of amyotrophic lateral sclerosis.